PTC299
- Generic Name
- PTC299
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 053QD2I96A
- Background
PTC299 is a novel, orally administered small-molecule designed to inhibit the production of vascular endothelial growth factor (VEGF) in tumors. Overexpression of VEGF plays a key role in multiple diseases including cancer and macular degeneration. PTC299 was discovered through PTC's GEMS technology by targeting the post-transcriptional processes that regulate VEGF formation, and is currently being developed for the treatment of cancer.
- Indication
Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath